CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Phase I trial of daily PI3Kα inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC).
Authors
Anne M. Covey
Betty Ann Caravella
+18 more
Clifford A. Hudis
Diana Lake
Emma J. Langley
Farrah Mikhail Datko
Gabriella D'Andrea
Jose Baselga
Mario E. Lacouture
Mary Ellen Moynahan
Maura N. Dickler
Michael F. Berger
Payal Deepak Shah
Phillip Sangwook Kim
Sarat Chandarlapaty
Shanu Modi
Sharat Singh
Shari Beth Goldfarb
Stephen Zamora
Sujata Patil
Publication date
Publisher
'American Society of Clinical Oncology (ASCO)'
Doi
Cite
Abstract
Abstract is not available.
Similar works
Full text
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 25/10/2020